House Panel Asks For ‘Prompt Review’ Of Evidence On Dense Breast Reporting
This article was originally published in The Gray Sheet
Executive Summary
The House Appropriations Committee May 29 approved a flat-level 2015 FDA spending bill. The committee’s report language for the bill urges the agency to expedite its review of evidence supporting the need for breast density reporting in individuals’ mammography reports, and to keep focus on artificial pancreas systems.
You may also be interested in...
Evidence Lacking To Assess Added Dense-Breast, 3-D Mammo Cancer Screens, Task Force Says
In a draft recommendation, the U.S. Preventive Services Task Force says evidence is "insufficient" to assess 3D tomosynthesis for breast cancer screening, as well as for additional dense-breast screening by any modality.
FDA, Congress Look To Nationalize Breast Density Reporting Requirements, Now In 13 States
FDA hopes to finish drafting a proposed rule by early next year requiring mammography screening professionals to notify women and their physicians of dense breast tissue that may warrant further imaging follow-up with MRI and ultrasound. Meanwhile, a bill was recently introduced in Congress on the same topic.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.